India launches its first indigenous CRISPR-based gene therapy for sickle cell disease

• India has launched its first indigenous CRISPR-based gene therapy for sickle cell disease.

• Science and Technology Minister Dr. Jitendra Singh launched the CRISPR-based gene therapy for sickle cell disease.

• This disease primarily affects the country's tribal population. The therapy is called BIRSA 101.

• BIRSA 101 pays tribute to Birsa Munda on his 150th birth anniversary.

• The launch of BIRSA 101 marks a significant milestone in India's efforts to eliminate sickle cell disease.

• International treatments cost ₹20-25 crore (200-250 million rupees). This makes this newly developed therapy relatively affordable.